JP7840259B2 - 光学分割されたトロロックス中間体およびその製造方法 - Google Patents

光学分割されたトロロックス中間体およびその製造方法

Info

Publication number
JP7840259B2
JP7840259B2 JP2022501092A JP2022501092A JP7840259B2 JP 7840259 B2 JP7840259 B2 JP 7840259B2 JP 2022501092 A JP2022501092 A JP 2022501092A JP 2022501092 A JP2022501092 A JP 2022501092A JP 7840259 B2 JP7840259 B2 JP 7840259B2
Authority
JP
Japan
Prior art keywords
formula
compound
trolox
amide solvent
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022501092A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021167095A1 (https=
JPWO2021167095A5 (https=
Inventor
貴一 黒田
潔人 澤村
信二郎 露峯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics Inc
Original Assignee
PTC Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PTC Therapeutics Inc filed Critical PTC Therapeutics Inc
Publication of JPWO2021167095A1 publication Critical patent/JPWO2021167095A1/ja
Publication of JPWO2021167095A5 publication Critical patent/JPWO2021167095A5/ja
Priority to JP2025232373A priority Critical patent/JP2026041900A/ja
Application granted granted Critical
Publication of JP7840259B2 publication Critical patent/JP7840259B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022501092A 2020-02-21 2021-02-19 光学分割されたトロロックス中間体およびその製造方法 Active JP7840259B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025232373A JP2026041900A (ja) 2020-02-21 2025-12-04 光学分割されたトロロックス中間体およびその製造方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020028614 2020-02-21
JP2020028614 2020-02-21
PCT/JP2021/006465 WO2021167095A1 (ja) 2020-02-21 2021-02-19 光学分割されたトロロックス中間体およびその製造方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025232373A Division JP2026041900A (ja) 2020-02-21 2025-12-04 光学分割されたトロロックス中間体およびその製造方法

Publications (3)

Publication Number Publication Date
JPWO2021167095A1 JPWO2021167095A1 (https=) 2021-08-26
JPWO2021167095A5 JPWO2021167095A5 (https=) 2024-02-29
JP7840259B2 true JP7840259B2 (ja) 2026-04-03

Family

ID=77390820

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022501092A Active JP7840259B2 (ja) 2020-02-21 2021-02-19 光学分割されたトロロックス中間体およびその製造方法
JP2025232373A Pending JP2026041900A (ja) 2020-02-21 2025-12-04 光学分割されたトロロックス中間体およびその製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025232373A Pending JP2026041900A (ja) 2020-02-21 2025-12-04 光学分割されたトロロックス中間体およびその製造方法

Country Status (8)

Country Link
US (1) US12509434B2 (https=)
EP (1) EP4108658A4 (https=)
JP (2) JP7840259B2 (https=)
KR (1) KR20220143897A (https=)
CN (1) CN115066420B (https=)
BR (1) BR112022016508A2 (https=)
IL (1) IL295785A (https=)
WO (1) WO2021167095A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20250133A (es) 2022-09-12 2025-06-26 Ptc Therapeutics Inc Granulos para suspension
AU2023352262A1 (en) 2022-09-30 2025-04-24 Ptc Therapeutics, Inc. Oxidative cleavage method of trolox amide
WO2025117870A1 (en) 2023-12-01 2025-06-05 Ptc Therapeutics, Inc. Method of electrolytic oxidative cleavage of trolox amide
WO2025193975A1 (en) 2024-03-13 2025-09-18 Ptc Therapeutics, Inc. Formulations for stabilizing dissolution of medicaments

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002167381A (ja) 2000-08-03 2002-06-11 Kuraray Co Ltd （±）−６−ヒドロキシ−２，５，７，８−テトラメチルクロマン−２−カルボン酸の光学分割法
JP2011503005A (ja) 2007-11-06 2011-01-27 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病を治療するための４−（ｐ−キノリル）−２−ヒドロキシブタンアミド誘導体
JP2012025705A (ja) 2010-07-26 2012-02-09 Tokuyama Corp （ｓ）−４−〔（４−クロロフェニル）（２−ピリジル）メトキシ〕ピペリジンのジアステレオマー塩の製造方法
JP2012508219A (ja) 2008-11-07 2012-04-05 シプラ・リミテッド ゾピクロンを分割するための方法
WO2014168103A1 (ja) 2013-04-10 2014-10-16 第一三共株式会社 ピロール誘導体の結晶及びその製造方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA739471B (en) * 1972-12-22 1974-08-28 Hoffmann La Roche Chromane derivatives
US3947473A (en) 1972-12-22 1976-03-30 Hoffman-La Roche Inc. Antioxidant chroman compounds
US4003919A (en) 1973-11-19 1977-01-18 Hoffmann-La Roche Inc. Antioxidant chroman compounds
US4026907A (en) 1973-11-19 1977-05-31 Hoffmann-La Roche Inc. Antioxidant chroman compounds
WO2002012221A1 (en) * 2000-08-03 2002-02-14 Kuraray Co., Ltd. Method for optical resolution of (±)-6-hydroxy-2,5,7,8-tetramethylcoumarone-2-carboxylic acid
JP5598330B2 (ja) * 2008-10-29 2014-10-01 三菱瓦斯化学株式会社 光学活性有機カルボン酸の製造方法
JPWO2013011999A1 (ja) * 2011-07-20 2015-02-23 株式会社カネカ 光学活性２−メチルプロリン誘導体の製造法
DK3233786T3 (da) * 2014-12-16 2022-05-09 Ptc Therapeutics Inc Polymorfe og amorfe former af (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6- dioxocyclohexa-1,4-dienyl)butanamid
EP3233819A1 (en) * 2014-12-16 2017-10-25 Bioelectron Technology Corporation Methods for chiral resolution of trolox
JP2020028614A (ja) 2018-08-24 2020-02-27 株式会社三共 遊技機

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002167381A (ja) 2000-08-03 2002-06-11 Kuraray Co Ltd （±）−６−ヒドロキシ−２，５，７，８−テトラメチルクロマン−２−カルボン酸の光学分割法
JP2011503005A (ja) 2007-11-06 2011-01-27 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病を治療するための４−（ｐ−キノリル）−２−ヒドロキシブタンアミド誘導体
JP2012508219A (ja) 2008-11-07 2012-04-05 シプラ・リミテッド ゾピクロンを分割するための方法
JP2012025705A (ja) 2010-07-26 2012-02-09 Tokuyama Corp （ｓ）−４−〔（４−クロロフェニル）（２−ピリジル）メトキシ〕ピペリジンのジアステレオマー塩の製造方法
WO2014168103A1 (ja) 2013-04-10 2014-10-16 第一三共株式会社 ピロール誘導体の結晶及びその製造方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
光学異性体の分離〔季刊 化学総説 Ｎｏ．６〕，株式会社 学会出版センター，1999年06月10日，pp. 45-54

Also Published As

Publication number Publication date
IL295785A (en) 2022-10-01
US12509434B2 (en) 2025-12-30
JPWO2021167095A1 (https=) 2021-08-26
JP2026041900A (ja) 2026-03-10
EP4108658A4 (en) 2024-05-22
WO2021167095A1 (ja) 2021-08-26
CN115066420A (zh) 2022-09-16
EP4108658A1 (en) 2022-12-28
CN115066420B (zh) 2024-12-10
KR20220143897A (ko) 2022-10-25
US20230029044A1 (en) 2023-01-26
BR112022016508A2 (pt) 2022-10-11

Similar Documents

Publication Publication Date Title
JP7840259B2 (ja) 光学分割されたトロロックス中間体およびその製造方法
AU2018234814B2 (en) Crystal forms of amino lipids
AU2015296289A1 (en) Coformer salts of (2S,3S)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them
WO2008062460A2 (en) Crystalline forms of pregabalin
JP2008239629A (ja) 新規なベンラファクシン塩酸塩多型形状、ならびにその調製方法
EP3169692A1 (en) A new form of sofosbuvir and a method of its preparation
JP6911033B2 (ja) 極性非プロトン性溶媒を用いたｎ−［４−（１−アミノエチル）−フェニル］−スルホンアミド誘導体のキラル分割方法
KR20100022081A (ko) 결정성 로티고틴 염기 및 이의 제조 방법
Wu et al. Synthesis, crystallization and characterization of diastereomeric salts formed by ephedrine and malic acid in water
EP3656768A1 (en) Beraprost-314d crystals and methods for preparation thereof
Szeleczky et al. Effect of ultrasound-assisted crystallization in the diastereomeric salt resolution of tetramisole enantiomers in ternary system with O, O′-dibenzoyl-(2R, 3R)-tartaric acid
JP2010132561A (ja) コハク酸シベンゾリンの新規ａ型結晶及びその製造方法
US11078152B2 (en) Method for resolution of baclofen salts
HK40079636A (en) Optically resolved trolox intermediate and method for producing same
JP7426832B2 (ja) 新規結晶構造を有するイグラチモド及びその製造方法
CN111995571A (zh) 一种瑞戈非尼与马来酸的共晶及其制备方法
JP4728548B2 (ja) 光学活性アミノアルコールの製造方法
TWI723455B (zh) 魯比前列酮(lubiprostone)晶體及其製備方法
BR122025015739A2 (pt) Método de fabricação de um sal sólido, compostos, solvatos e ingredientes farmaceuticamente aceitáveis
JP2021526513A (ja) ティピファニブの合成
JP2006169251A (ja) 一方のエナンチオマーを他方より多く含む２−フルオロカルボン酸エステルの製造方法
Harfouche Non-Classical Studies for Cyclic Preferential Crystallization of a Stable Racemic Compound
JP4997463B2 (ja) ピリジン酸化型化合物、並びに、これを用いたカルボン酸誘導体及びその光学活性体の製造方法
CN120058609A (zh) 一种(r)-5-环戊基吡唑烷-3-酮的药用盐及其制备方法和用途
JP2021161097A (ja) テネリグリプチンの新規結晶形及びその製造方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220922

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20230830

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240219

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20241105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260324

R150 Certificate of patent or registration of utility model

Ref document number: 7840259

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150